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Abstract 
Counterfeit medicines represent a global public health threat warranting the 
development of accurate, rapid and non-destructive methods for their identification. 
Portable near-infrared spectroscopy near-infrared spectroscopy offers this advantage. 
This work sheds light on the potential of combining NIRS with Principal Component 
Analysis (PCA) and Soft Independent Modelling of Class Analogy (SIMCA) for 
authenticating branded and generic antibiotics. A total of 23 antibiotics were measured 
‘non-destructively’ using a portable NIR spectrometer. The antiobiotics corresponded 
to six different active pharmaceutical ingredients being: amoxicillin trihydrate and 
clavulanic acid; azithromycin dihydrate; ciprofloxacin hydrochloride; doxycycline 
hydrochloride and ofloxacin.  NIR Spectra where exported into Matlab R 2018b where 
data analysis was applied. The results showed that the NIR spectra of the medicines 
showed characteristic features corresponds to the main excipient(s). When combined 
with PCA, NIRS could distinguish between branded and generic medicines and could 
classify medicines according to their manufacturing sources. The PCA scores showed 
the distinct clusters corresponding to each group of antibiotics whereas the loadings 
indicated which spectral features were significant. SIMCA provided more accurate 
classification over PCA for all antibiotics except ciprofloxacin which products shared 
many overlapping excipients. In summary, the findings of the study demonstrated the 
feasibility of portable NIRS as an initial method for screening antibiotics.  
 
Keywords 
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Introduction 
Medicine counterfeiting represents a global expanding problem with increased 
morbidity and mortality worldwide. The impact of counterfeit medicines can result 
in lethal consequences in its worst. A counterfeit medicine is defined by the World 
Health Organisation (WHO) as “deliberately/fraudulently misrepresent their 
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identity, composition or source” [1]. A substandard medicine is also known as poor 
quality medicine that failed to satisfy its manufacturing specifications [1-3]. 
Medicine counterfeiting can occur to any class of medicines, of any formulation 
and any source. Antibiotics represent one of the main classes of medicines sold in 
both developed and developing countries; thus, have high probability of being 
substandard or counterfeited [4-8]. Counterfeit and substandard antibiotics can be 
encountered anywhere in the world, and may not be limited to the lack of active 
pharmaceutical ingredients (APIs) but also may have defects in the excipients or 
physical characteristics of the products. The consequences of using counterfeit 
antibiotics can range from decreased efficacy [9,10]; treatment failure [11-14]; 
antimicrobial resistance development [5,15] and lethal consequences [10,15-16].  
The literature revealed few methods for antibiotics authentication. These methods 
range from simple colour tests to mass spectrometric methods. Colour tests and 
thin layer chromatography have been used for detecting macrolides [17]; 
amoxicillin and co-trimoxazole [18]; and fluoroquinolones [19]. Likewise 
inexpensive test cards were used for determination of beta lactam antibiotics 
[20].Colour tests were sometimes used alongside dissolution testing and the GPHF 
Minilab that was used for screening of specific classes of antibiotics such as 
amoxicillin and co-trimoxazole [18] and/or multiple classes [21,22]. More 
sophisticated techniques used for analysis of counterfeit and substances 
antibiotics included high performance liquid chromatography [18,23-25], ultra-high 
performance liquid chromatography [26], liquid chromatography mass 
spectrometry [27] and capillary electrophoresis [28].  
However, all the aforementioned techniques were destructive to the samples 
analysed and/or required extensive method development. Portable near-infrared 
spectroscopy (NIRS) offers an advantage over the previous mentioned techniques 
in being rapid, mobile and a non-destructive technique. NIRS offers a further 
advantage over alternative chemical techniques in being able to characterise the 
physical properties alongside the chemical characteristics of the sample analysed. 
Limited studies utilised NIRS for authenticating antibiotics such as ciprofloxacin 
[29,30]; fluoroquinolones [31]; macrolides [32]. However, the three aforementioned 
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studies focused on one class of antibiotics and with one multivariate data analysis 
algorithm. Thus, there is still a need to look at a collective method that can 
authenticate diverse classes of antibiotics. This work aimed to evaluate NIRS and 
multivariate classification algorithms for authentication of antibiotics purchased 
worldwide. 
 
Theory 
Spectral pre-treatment 
Multiplicative Scatter Correction – First Derivative (MSC-D1) spectral pre-
treatment approach was applied in order to correct for the offset and baseline in 
the spectra that changes depending on several factors including the sample age, 
thickness and optical properties; temperature; moisture content and performance 
of the instrument [33,34]. MSC corrected the offset of the scattered light by 
construction of a new spectrum that is a linear combination of the original spectrum 
according to the equation [35,36]: 
𝑦𝑀𝑆𝐶,𝑖 =  
(𝑦𝑖 − 𝑎)
𝑏
 
Where :   yMSC,i is the corrected spectrum value  
               yi is the original spectrum value 
               a is the intercept of the line 
               b is the slope of the line 
 
First derivative was corrected both the offset and baseline of the NIR spectra using 
Savitzky-Golay method where a second order polynomial was fitted to the data by 
least square using 13 data points  [35]. 
 
Correlation in Wavenumber Space (CWS) 
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CWS method matched the correlation coefficient (r) value of the test spectrum (A) 
and a reference spectrum (B). It was calculated as the momentum product (rp) 
between both spectra according to the equation [35,37]: 
𝑟𝑝 =  
∑(𝐴𝑖 − ?̅?)(𝐵𝑖 − ?̅?)
√∑(𝐴𝑖 − ?̅?)2 ∑(𝐵𝑖 − ?̅?)2
 
An r value of -1 meant that the spectra were completely dissimilar whereas an r 
value of +1 meant that the spectra were identical. In this work, an r value of 0.95 
was taken as a match among products because it was difficult to get +1 among 
identical samples due to noise in the spectra [35,37]. For evaluation of CWS 
method, type I and type II errors were explored [30]. Type I errors (known as false 
positives) were encountered when an authentic antibiotic was misidentified by the 
algorithm (i.e. gave r values < 0.95). On the other hand, type II errors (known as 
false negatives) were encountered when a counterfeit sample were identified as 
authentic (i.e. gave r values > 0.95). 
 
Principal Component Analysis (PCA)  
PCA classified data by reducing its dimensionality into two subspaces being 
scores and loadings. The scores showed the distribution of the antibiotics in 
multidimensional space and the loadings showed significant absorbance values 
corresponding to the significant constituents (influencers) within the models. PCA 
was applied to the MSC-D1 spectra of the products in order to visualise patterns 
on classification among the products. As with CWS method, PCA was evaluated 
for type I and type II errors [30]. In this case, type I error was encountered when 
an authentic antibiotic was not clustered with authentic antibiotics. Moreover, a 
type II error was encountered when a counterfeit antibiotic was clustered with the 
authentic ones. 
 
Soft Independent Modelling of Class Analogy (SIMCA) 
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SIMCA is a chemometric approach, based on PCA, which models the variation 
within the collection of reference spectra for a given material, as well as the 
difference between spectra of different materials [38]. This allows SIMCA to be 
sensitive to small spectral differences, even batch-to-batch or sampling variations. 
New samples can then be classified to one (or none) of the established class 
models, based on their similarity to the respective model. This is achieved by 
investigating the size of its residual, as well as its location on the scores map.  
 
Materials and Methods 
Materials 
A total of 23 antibiotic products containing six different APIs were used in this study 
(Table 1). The APIs of the antibiotics included: amoxicillin trihydrate and clavulanic 
acid; azithromycin dihydrate; ciprofloxacin hydrochloride; doxycycline 
hydrochloride and ofloxacin. The antibiotic products were obtained from 11 
different countries: Austria; France; Germany; Ghana; India; Italy; Jordan; 
Lebanon; Spain; UAE and the UK. The products were either tablets or capsules 
and included both branded and generic medicines. Regards the excipients, 19 
products had between seven and 10 excipients each (Table 2). The excipients of 
the remaining four products were not reported. In total, 29 excipients were present 
in at least one or more products (Appendix A). The recurrent excipients were 
hypromellose, magnesium stearate, maize starch and titanium dioxide. 
 
Near infrared spectroscopic analysis 
NIR spectra of antibiotic products and their individual constituents were collected 
using the PerkinElmer Spectrum Two NTM FT-NIR instrument equipped with NIR 
reflectance module (NIRM). Tablet formulations were measured as received from 
both sides. The contents of each capsule formulation were emptied into glass vials 
and were measured through the vials. Likewise, excipients were powders and were 
measured via glass vials. Two spectra were collected per each tablet and three 
 
 
 
7 
spectra per each vial over the wavenumber range of 10,000 – 4000 cm-1 with 
spectral resolution of 8 cm-1. Each spectrum was the sum of 32 scans. 
 
Data analysis 
Spectra were exported into Matlab R2018b where data pre-treatment was applied. 
Pre-treatment of spectra was made using MSC-D1. Multivariate data analysis was 
conducted using CWS; PCA; and SIMCA methods. CWS was applied to the MSC-
D1 spectra in Matlab R2018b where the r values of products were compared and 
an r value of 0.95 was considered a threshold. PCA were applied in Matlab R2018b 
where clustering among antibiotics was evaluated. SIMCA analysis was carried out 
using PerkinElmer AssureIDTM materials verification software to create five PCA 
models of the antibiotic products. A global PCA of all materials was also created to 
provide an overview of the complete model and understand relationships between 
material types. The threshold taken for inter-material distances was 1.5 where a 
distance below 1.5 was considered a similarity. MSC normalisation and first 
derivative (13-point) baseline correction were applied to the raw spectra of the 
antibiotic products. 
 
Results and Discussion 
Diversity of the sample set relating to the APIs and excipients 
In order to evaluate the identification potential of the method, 23 antibiotic products 
relating to five APIs were chosen. The products were of both branded and generic 
types, of tablet and/or capsule formulations and were obtained from different 
sources across the wholesale supply chain including community pharmacies, 
hospital pharmacies, humanitarian aid supply, online pharmacies, street market 
and wholesalers (Table 1). The APIs of the evaluated products were: amoxicillin 
trihydrate and clavulanic acid (AMC); azithromycin dehydrate (AZ); ciprofloxacin 
hydrochloride (CIP); doxycycline hydrochloride (DOX) and ofloxacin (OFL). The 
numbers of products per antibiotic varied between two and 12 products for each 
API depending on availability and were: Two for each of DOX and OFL, three for 
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AMC, four for AZ and 12 for CIP. In some cases, the aforementioned products had 
overlapping excipients (Table 2). Excipients were always reported for branded but 
not generic products. Where reported, the minimum number of excipients per 
product was six and the maximum was 10. However, in most cases the main 
excipients were consistent among products of the same API. For instance, AMC 
products (AMC1, AMC2 and AMC3) were from three different manufacturers in 
Lebanon, Spain and the UK and had overlapping excipients being: hypromellose, 
microcrystalline cellulose (MCC), magnesium stearate (MgS) and titanium dioxide. 
Likewise, OFL products (OFL1 and OFL2) were from two different manufacturers 
and had six common excipients being: croscarmellose sodium, hypromellose, 
lactose, maize starch, MCC and titanium dioxide. CIP branded products (CIP1-
CIP5) were all from the same manufacturer and had the same list of excipients. 
Three generic CIP products (CIP7, CIP8 and CIP9) had common excipients as 
branded CIP products being: crospovidone, colloidal anhydrous silica, 
hypromellose, macrogol 4000, maize starch, MgS, MCC and titanium dioxide. On 
the other hand, AZ products (AZ1, AZ2, AZ3 and AZ4) were manufactured by two 
manufacturers and showed different excipients between both manufacturers.  
Moreover, CIP11 and CIP12 had different list of excipients to the other CIP 
products. The excipients were not reported for CIP6, CIP10, DOX1 and DOX2 that 
were manufactured by generic manufacturers.  
 
Spectral evaluation 
The spectra of the antibiotic products showed characteristics for their main 
excipients that were key in identifying the products using NIRS (Appendix B). 
Hence, NIRS offered the advantage of giving more information on the samples’ 
constituents including the API and excipients. Thus, it could serve as a 
fingerprinting in spectral identification [39]. This was confirmed when the branded 
medicine of each antibiotic was compared against its main excipient (Figure 1). 
However, the degree of match depended on the amount of API or excipients in the 
product. OFL1 showed spectral similarity for MCC and maize starch with 
correlation coefficient (r) values of 0.73 and 0.69 respectively that confirmed that 
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these excipients were present in adequate amounts. Likewise, DOX1 showed 
spectral similarity for MCC and maize starch with r values of 0.71 and 0.75 
respectively. However, excipients that were present in low amounts within a tablet 
did not show peaks in the NIR spectra of the tablets. For instance, talc was present 
in OFL1 but no characteristic peak for it was seen within its spectra.  
 
Authentication of branded antibiotic products 
PCA was successful in showing the chemical variation between different 
antibiotics. The PCA model showed good classification following MSC-D1 
treatment of the data. The first three PCs contributed to 89.2% of the variance with 
76.4% of the variance explained by PC1 and PC2. Figure 2 shows the 2D and 3D 
scores plots of AMC1; AZ1; CIP1; DOX1 and OFL1. A distinct cluster was observed 
for each antibiotic product and that showed the effectiveness of PCA in 
differentiating between the five authentic products (Figure 2). The highest variance 
on PC1 was observed for the CIP1 cluster. This was followed by the clusters 
corresponding to AMC1, DOX1 and OFL1 that were neighbouring each other. 
AMC1 and OFL1 contained around 50% of API and 50% of excipients. Two 
excipients were common among both products and were MgS and hypromellose. 
This also could indicate that DOX had similar excipients to AMC and OFL. To 
interpret the influences of individual constituents on antibiotic products, PC loading 
plots were visualised. Figure 3 shows the PC1 loading plot of the different antibiotic 
PCA model that corresponded to 51.2% of the variance. The aforementioned PC1 
loading showed contribution over the wavenumber ranges of 9172-8124 cm-1; 
7572-6502 cm-1; 6260-5632 cm-1; 5340-4880 cm-1; and 4752-4016 cm-1. The 
aforementioned five regions showed spectral features corresponding to MgS; 
ciprofloxacin and MCC; ciprofloxacin and lactose; amoxicillin and ciprofloxacin 
(Appendix B). This suggested that the five antibiotic products could be principally 
separated on the basis of differences in their APIs and excipients. 
Taking the aforementioned model forward, the next step was to classify the 
branded and generic medicines for each antibiotic and look into tracking their 
manufacturing sources (Figures 4 and 5). The discriminative capability of PCA 
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depended on sample size and sample type [37]. For both AMC and AZ products, 
two distinct clusters were seen between the branded and generic products (Figure 
4 a and b). AMC1, AMC2 and AMC3 showed three distinct clusters that confirmed 
their three distinct manufacturing sources being the UK, Lebanon and Spain. The 
PC1 loading (95.2% of the variance) showed characteristic features for amoxicillin, 
MCC and talc (Appendix A, Appendix B). Amoxicillin spectral features were seen 
in the regions of 8910-8378 cm-1; 6178-5636 cm-1; and 5334-5082 cm-1. Talc 
spectral features were featured at 7318-6992 cm-1; whereas MCC spectral features 
were seen at 4550-4000 cm-1. Moreover, the PCA scores plot of AZ showed three 
distinct clusters that corresponded to both their manufacturing sources and 
formulation type. In this respect, AZ3 and AZ4 products were clustered together 
where both products were capsules and manufactured by the same manufacturer. 
Two distinct clusters were seen for AZ1 and AZ2 which were both of tablet 
formulation but manufactured by two different manufacturers. It is noteworthy to 
mention here that AZ2 had the same manufacturer as AZ3 and AZ4 but was of 
tablet instead of capsule formulation. This confirmed the ability of NIR to distinguish 
physical differences between samples of the same chemical makeup [40]. The PC1 
loading plot of AZ products (75.2% of the variance) 7270-7138 cm-1 corresponding 
to talc that was an excipient in AZ1 (of tablet formulation) (Appendix A). Additional 
spectral features in the PC1 loading plot were seen in the regions of 8804-8350 
cm-1; 7074-6800 cm-1; 6584-6290 cm-1; 6064-5646 cm-1; 5334-5004 cm-1; 4984-
4668 cm-1; and 4550-4668 cm-1. The aforementioned seven regions corresponded 
to lactose. DOX products scores plot showed type I error in the cluster of one 
product (Figure 4c). Hence, DOX1 and DOX2 products were separated in three 
clusters (instead of two) where DOX1 was separated in two distinct clusters. The 
PC1 loading of DOX products (90.7% of the variance) showed characteristic 
features for talc in the region of 7242-7088 cm-1. Other features for this PC1 loading 
were seen in the region of 6156-5670 cm-1; 5348-4750 cm-1; and 4650-4000 cm-1. 
The aforementioned three regions corresponded to lactose and MCC. 
Nonetheless, OFL1 and OFL2 products were clustered into two distinct clusters 
that corresponded to their manufacturing sources being the UK and France 
respectively (Figure 4d). However, type I error was encountered in this latter PCA 
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score plot where both products had outlier(s) within their score plot. The PC1 
loading (82.9% of the variance) of OFL products showed characteristic spectral 
features for talc in the region of 7246-7136 cm-1. Additional peaks were seen in the 
regions of 6170-5598 cm-1; 5312-5124 cm-1; and 4752-4000 cm-1. The 
aforementioned three regions corresponded to lactose. 
In addition to identifying manufacturing source and discriminating branded from 
generic medicines; the potential for NIR and PCA for spotting a potential counterfeit 
product was demonstrated through the PCA scores plot of CIP products (Figure 
5). In this sense, the PCA score of a CIP branded product (CIP5) overlapped with 
one of the generic products. In order to address this overlap, the PC1 loading 
(67.8% of the variance) of the CIP products had been examined and had shown a 
major influence of 7260-7150 cm-1 that is characteristic for talc (Marjo et al. 2008). 
It is noteworthy to mention in this case that talc was not listed in the label claim of 
any of the branded products. Talc had been found in counterfeit antibiotics as it is 
cheap and increases the bulk of the medicine (Kovacs et al. 2014; Weaver et al. 
2013). Therefore, CIP5 did not match the manufacturers’ specification relating to 
the identity and could be counterfeit [30].   
 
Development of SIMCA classification models 
To further address the type I error encountered with PCA, PCA was taken forward 
and SIMCA models were constructed. The first SIMCA model showed agreement 
with PCA Model 1. Hence, distinct classification of the five branded products was 
observed with no overlapping materials. SIMCA provided a further advantage over 
PCA in detecting type I and type II errors in classification of different products [41]. 
In this respect, the distances between the five products were calculated and were 
found above zero and this showed no type I or type II errors (Table 3). Hence table 
3 showed all distances above the threshold that was 1.5. Successively, individual 
SIMCA models were applied to each antibiotic (Figure 6). For AMC products, the 
global PCA showed three distinct PCs for AMC1, AMC2 and AMC3 that confirmed 
their different manufacturing sources. The four AZ products showed three distinct 
clusters: one corresponding to AZ1, second to AZ2 and the third to AZ3 and AZ4. 
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AZ3 and AZ4 were of the same formulation (both capsules) and had the same 
manufacturer but purchased in different countries; therefore, SIMCA was further 
successful in detecting differences in manufacturing sources and formulation. On 
the other hand, misclassification was observed among CIP branded and generic 
products where no clear clustering was observed between both groups of products. 
Two products were misclassified and seen as two distinct clusters (CIP 6 and CIP 
10) and that denoted type I error. Moreover, the aforementioned model could not 
distinguish the counterfeit CIP batch (CIP 5) that indicated type II error. Likewise, 
type I error was observed for DOX global PCA where DOX1 was scattered in two 
distinct clusters. On the other hand, OFL1 and OFL2 products were separated 
between two individual clusters that corresponded to their different manufacturing 
sources.  
 
Conclusion 
The findings of the study demonstrated the effectiveness of portable NIRS and 
chemometrics as a tool in authenticating antibiotics. The combination of NIRS with 
PCA and SIMCA proved to be efficient in discriminating branded from generic 
medicines and in tracking the manufacturing sources of medicines. Moreover, the 
algorithms could give initial indication for the presence of a potential counterfeit. 
However, some limitations were encountered in this study. The first limitation 
related to sample size and sourcing of the samples that had been a challenge 
especially that the medicines had been sought from different countries. The second 
limitation related to the precision of classifying authentic products particularly with 
large datasets with overlapping excipients such as CIP. Other limitations were 
associated with the sensitivity of NIRS for characterising constituents where 
constituents with low amounts in a medicine will not show spectral features. In 
summary, portable NIRS could serve as an initial screening method for 
authentication of antibiotics saving time and money associated with importing the 
samples to the laboratory. However, for identity confirmation of the API in 
antibiotics more quantitative techniques are needed. 
Acknowledgement 
 
 
 
13 
The authors would like to thank Annalene Salter, Adam Naughton, Thomas Coombs 
and Tiffany Cullern for their contribution to the spectral collection.  
 
Funding 
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. 
 
Conflict of interest 
The authors declare that they have no conflict of interest. 
 
 
References 
[1]        WHO. 2017. Definitions of substandard and falsified medical products. 
Geneva, Switzerland. 
[2]          J. Videau, Generic drugs: the hidden issues of quality and cost. WHO drug 
information. (2000) 14(2):77. 
[3]          World Health Organization.. Quality assurance of pharmaceuti- cals, vol 2. 
(1999a) World Health Organization, Geneva, Switzerland. 
[4]           H. Frankish, The Lancet, WHO steps up campaign on counterfeit drugs 
(2003) 22;362(9397):1730. 
[5]           T. Kelesidis, L. Kelesidis, P. Rafailidis, M. Falagas, Counterfeit or 
substandard antimicrobial drugs: a review of the scientific evidence, J Antimicrob. 
Chemother. 60 (2007) 214–236. 
[6]            World Health Organization, Counterfeit drugs: guidelines for the 
development of measures to combat counterfeit drugs (1999b). Geneva: World 
Health Organization. 
[7]            S. Pincock, BMJ, WHO tries to tackle problem of counterfeit medicines in 
Asia. (2003) 15;327(7424):1126. 
 
 
 
14 
[8]            E. Wondemagegnehu, WHO Report. Counterfeit and substandard drugs in 
Myanmar and Vietnam. WHO/EDM/QSM. (1999) 99. 
[9]            L. Basco, P. Ringwald, A. Manéné, J. Chandenier. False chloroquine 
resistance in Africa. The Lancet (1997) 19;350(9072):224. 
[10] M. Issack. Substandard drugs. The Lancet. (2001) 27;358(9291):1463. 
[11] O. Shakoor, R. Taylor, R. Behrens. Assessment of the incidence of 
substandard drugs in developing countries. Tropical Medicine & International 
Health. (1997) 2(9):839-45. 
[12] D. Menkes, Hazardous drugs in developing countries: The market may be 
healthier than the people (1997). 
[13] A. Po, Too much, too little, or none at all: dealing with substandard and fake 
drugs. The Lancet. (2001) Jun 16;357(9272):1904. 
[14] B. Stenson, B. Lindgren, L. Syhakhang, G. Tomson, The quality of drugs in 
private pharmacies in the Lao People’s Democratic Republic. International Journal 
of Risk & Safety in Medicine. (1998) 1;11(4):243-9. 
[15] A. Delepierre, A. Gayot, A. Carpentier, Update on counterfeit antibiotics 
worldwide; public health risks. Medecine et maladies infectieuses. (2012) 
1;42(6):247-55. 
[16] Pharmaceutical Security Institute, Counterfeit situation. (2014). 
<http://www.psi-inc.org/counterfeitSituation.cfm>.  
[17] C. Hu, W. Zou, W. Hu, X. Ma, M. Yang, S. Zhou, J. Sheng, Y. Li, S. Cheng, J. 
Xue, Establishment of a fast chemical identification system for screening of 
counterfeit drugs of macrolide antibiotics. Journal of pharmaceutical and biomedical 
analysis. (2006) 23;40(1):68-74. 
[18] I. Fadeyi, M. Lalani, N. Mailk, A. Van Wyk, H. Kaur, Quality of the antibiotics—
amoxicillin and co-trimoxazole from Ghana, Nigeria, and the United Kingdom. The 
American journal of tropical medicine and hygiene. (2015) 3;92(6_Suppl):87-94. 
[19] B. Singh, D. Parwate, S. Shukla, Rapid color test identification system for 
screening of counterfeit fluoroquinolone. Journal of Chemistry. (2009) 6(2):377-84. 
[20] A. Weaver, H. Reiser, T. Barstis, M. Benvenuti, D. Ghosh, M. Hunckler, B. Joy, 
L. Koenig, K. Raddell, M. Lieberman, Paper analytical devices for fast field 
 
 
 
15 
screening of beta lactam antibiotics and antituberculosis pharmaceuticals. 
Analytical chemistry. (2013) 18;85(13):6453-60. 
[21] H. Pan, W. Ba-Thein, Diagnostic accuracy of Global Pharma Health Fund 
Minilab™ in assessing pharmacopoeial quality of antimicrobials. The American 
journal of tropical medicine and hygiene. (2018) 10;98(1):344-8. 
[22] F. Khuluza, S. Kigera, L. Heide, Low prevalence of substandard and falsified 
antimalarial and antibiotic medicines in public and faith-based health facilities of 
southern Malawi. The American journal of tropical medicine and hygiene. (2017) 
3;96(5):1124-35. 
[23] M. Gaudiano, A. Di Maggio, E. Antoniella, L. Valvo, P. Bertocchi, L. Manna, M. 
Bartolomei, S. Alimonti, A. Rodomonte, An LC method for the simultaneous 
screening of some common counterfeit and sub-standard antibiotics: validation and 
uncertainty estimation. Journal of pharmaceutical and biomedical analysis. (2008) 
29;48(2):303-9. 
[24] S. Schäfermann, E. Wemakor, C. Hauk, L. Heide, Quality of medicines in 
southern Togo: Investigation of antibiotics and of medicines for non-communicable 
diseases from pharmacies and informal vendors. PloS one. (2018) 
29;13(11):e0207911. 
[25] N. Tshilombo, P. Hamuli, J. Mbinze, V. Habyalimana, D. Kalenda, D. Mavungu, 
P. Mwamba, P. Hubert, Investigation of the Quality of Antibiotics-Based Amoxicillin 
for Monitoring of Some Different Medicine Markets of Democratic Republic of 
Congo. American Journal of Analytical Chemistry. (2018) 3;9(08):366. 
[26] J. Mbinze, P. Lebrun, B. Debrus, A. Dispas, N. Kalenda, J. Mbay, R. Marini, 
Application of an innovative design space optimization strategy to the development 
of liquid chromatographic methods to combat potentially counterfeit nonsteroidal 
anti-inflammatory drugs. Journal of Chromatography A. (2012) 1263, 113-124. 
[27] S. Bekoe, S. Bak, E. Björklund, K. Krogh, N. Okine, R. Adosraku, B. Styrishave, 
M. Hansen, Determination of thirteen antibiotics in drug products–A new LC-MS/MS 
tool for screening drug product quality. Analytical Methods. (2014) 6(15):5847-55. 
[28] A. Solangi, S. Memon, M. Khuhawar, M. Bhanger, Quantitative analysis of eight 
cephalosporin antibiotics in pharmaceutical products and urine by capillary zone 
electrophoresis. Acta Chromatographica. (2007) 1;19:81. 
 
 
 
16 
[29] S. Assi, R. Watt, A. Moffat, Assay of ciprofloxacin in intact and powdered tablets 
by near-infrared spectroscopy. Journal of Pharmacy and Pharmacology. (2008). 
[30] S. Assi, R. Watt, A. Moffat. Identification of counterfeit medicines from the 
Internet and the World market using near-infrared spectroscopy. Analytical 
Methods. (2011) 3(10):2231-6. 
[31] T. Sakamoto, Y. Fujimaki, Y. Hiyama, NIR spectroscopic investigation of two 
fluoroquinolones, levofloxacin and ofloxacin, and their tablets for qualitative 
identification of commercial products on the market. Die Pharmazie-An International 
Journal of Pharmaceutical Sciences. (2008) Sep 1;63(9):628-32. 
[32] H. Yang, B. Hu, X. Pan, S. Yan, Y. Feng, X. Zhang, L. Yin, C. Hu, Deep belief 
network-based drug identification using near infrared spectroscopy. Journal of 
Innovative Optical Health Sciences. (2017) Mar 28;10(02):1630011. 
[33] United States Pharmacopeia (USP), (2008). United States Pharmacopeial 
Convention. Inc, Rockville, MD. 
[34] Near-infrared spectrophotometry in the British Pharmacopoeia, The British 
Pharmacopoeia Comission, Stationery Office, Norwich, (2010) A150-A154. 
[35] R. Jee, Near-infrared spectroscopy in A. Moffat, M. Osselton, and B. Widdop 
(Eds.), Clarke's Analysis of Drugs and Poisons, 3rd edition, Pharmaceutical Press, 
London, (2004) 346-357. 
[36] K. Varmuza, P. Filzmoser, Introduction to multivariate statistical analysis in 
chemometrics. CRC press (2016). 
[37] R. Brereton, Consequences of sample size, variable selection, and model 
validation and optimisation, for predicting classification ability from analytical data. 
TrAC Trends in Analytical Chemistry. (2006) 1;25(11):1103-11. 
[38] A. Pomerantsev, O. Rodionova. Concept and role of extreme objects in 
PCA/SIMCA. Journal of Chemometrics. (2014) 28(5):429-38. 
[39] O. Rodionova, L. Houmøller, A. Pomerantsev, P. Geladi, J. Burger, V. 
Dorofeyev, A. Arzamastsev, NIR spectrometry for counterfeit drug detection: a 
feasibility study. Analytica Chimica Acta. (2005) 6;549(1-2):151-8. 
[40] A. Moffat, S. Assi, R. Watt, Identifying counterfeit medicines using near infrared 
spectroscopy. Journal of Near Infrared Spectroscopy. (2010) Feb 1;18(1):1-5. 
 
 
 
17 
[41] O. Rodionova, K. Balyklova, A. Titova, A.Pomerantsev, Quantitative risk 
assessment in classification of drugs with identical API content, 
J.Pharm.Biomed.Anal.98 (2014)186–192. 
Weaver Aa, Reiser H, Barstis TL, Benvenuti M, Ghosh D, et al. (2013) Paper 
analytical devices for fast field screening of beta lactam antibiotics and anti-
tuberculosis pharmaceuticals. Anal Chem 10.1021/ac400989p 
Kovacs, S., Hawes, S.E., Maley, S.N., Mosites, E., Wong, L. and Stergachis, A., 
2014. Technologies for detecting falsified and substandard drugs in low and middle-
income countries. PloS one, 9(3), p.e90601. 
Marjo J. Vredenbregt, Dennis Mooibroek and Ronald Hoogerbrugge 
Donald A. Burns, Emil W. Ciurczak (Eds.), Handbook of Near-Infrared 
Spectroscopy, CRC Press Taylor & Francis Group, Boca Raton (2008), pp. 631-
645 
 
 
 
 
18 
 
List of tables 
Table 1. Details of the antibiotics used in the study 
AN API Dose 
(mg) 
B/G Manufacturing 
place 
Source Formulation 
type 
AMC1 amoxicillin 
trihydrate/ 
clavulanic acid 
500/  
125 
B UK Lebanon/ 
Community 
pharmacy 
tablet 
AMC2 amoxicillin 
trihydrate/ 
clavulanic acid 
500/  
125 
G Lebanon Lebanon/ 
Humanitarian 
aid 
tablet 
AMC3 amoxicillin 
trihydrate/ 
clavulanic acid 
500/  
125 
G Spain Lebanon/ 
Humanitarian 
aid 
tablet 
AZ1 azithromycin 
dihydrate 
250 G UK UK/ 
wholesaler 
tablet 
AZ2 azithromycin 
dihydrate 
250 B Italy Italy/ 
wholesaler 
tablet 
AZ3 azithromycin 
dihydrate 
250 B Italy Italy/ 
wholesaler 
capsule 
AZ4 azithromycin 
dihydrate 
250 B Italy Italy/ 
wholesaler 
capsule 
CIP1 ciprofloxacin 
hydrochloride 
500 B Germany UK/ 
wholesaler 
tablet 
CIP2 ciprofloxacin 
hydrochloride 
500 B Germany UK/ 
wholesaler 
tablet 
CIP3 ciprofloxacin 
hydrochloride 
750 B Germany UK/ online 
pharmacy 
tablet 
CIP4 ciprofloxacin 
hydrochloride 
500 B Germany UK/ online 
pharmacy 
tablet 
CIP5 ciprofloxacin 
hydrochloride 
250 B Germany UK/ online 
pharmacy 
tablet 
CIP6 ciprofloxacin 
hydrochloride 
500 G Ghana Ghana/ 
street market 
tablet 
CIP7 ciprofloxacin 
hydrochloride 
500 G UAE Saudi 
Arabia/ 
hospital 
pharmacy 
tablet 
CIP8 ciprofloxacin 
hydrochloride 
500 G India UK/ 
wholesaler 
tablet 
CIP9 ciprofloxacin 
hydrochloride 
500 G UK UK/ 
community 
pharmacy 
tablet 
CIP10 ciprofloxacin 
hydrochloride 
250 G India Lebanon/ 
Humanitarian 
aid 
tablet 
CIP11 ciprofloxacin 
hydrochloride 
500 G UK UK/ 
community 
pharmacy 
tablet 
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CIP12 ciprofloxacin 
hydrochloride 
500 G UK UK/ 
community 
pharmacy 
tablet 
DOX1 doxycycline 
hydrochloride 
100 G Jordan Lebanon/ 
Humanitarian 
aid 
capsule 
DOX2 doxycycline 
hydrochloride 
100 G Austria Lebanon/ 
community 
pharmacy 
capsule 
OFL1 ofloxacin 200 G UK UK/ 
wholesaler 
tablet 
OFL2 ofloxacin 200 B France UK/ 
wholesaler 
tablet 
AM: Amoxicillin, API: Active pharmaceutical ingredient, AZ: Azithromycin, B: Branded, G: Generic, CIP: Ciprofloxacin, DOX: 
Doxycycline, OFL: Ofloxacin, UAE: United Arab Emirates. 
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Table 2. List of excipients studied in the investigated antibiotics 
Excipient/AN AMC
1 
AMC
2 
AMC
3 
AZ
1 
AZ
2 
AZ
3 
AZ
4 
CIP
1 
CIP
2 
CIP
3 
CIP
4 
CIP
5 
CIP
6 
CIP
7 
CIP
8 
CIP
9 
CIP1
0 
CIP1
1 
CIP1
2 
DOX
1 
DOX
2 
OFL
1 
OFL
2 
Butyl  hydroxy toluene                                               
Calcium hydrogen 
phosphate 
                                              
Carmellose NS300                                               
Colloidal  silicon 
dioxide 
                                              
Croscarmellose sodium                                               
Crospovidone                                                
Dimethicone                                               
Ethanol 96%                                               
Ethyl cellulose                                               
Gelatin                                               
Hyprolose                                               
Hypromellose                                               
Lactose monohydrate                                               
Macrogol 3000                                               
Macrogol 4000                                               
Macrogol 6000                                               
Macrogol 8000                                               
Maize starch                                               
MCC                                               
MgS                                               
Propylene glycol                                               
Sodium citrate                                               
Sodium lauryl sulfate                                               
Sodium starch 
glycolate 
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Sodium stearyl 
fumarate 
                                              
Talc                                               
Titanium dioxide                                               
Triacetin                                               
Triethyl citrate                                               
Total number of 
excipients 
9 10 10 6 6 6 6 8 8 8 8 8 NR 9 8 8 NR 7 7 NR NR 9 9 
AMC: amoxiciilin/clavulanic acid; AN: antibiotic number; AZ: azithromycin; CIP: ciprofloxacin, DOX: doxycycline; MgS: magnesium stearate; MCC: microcrystalline cellulose; NR: not reported; OFL: 
ofloxacin 
 
Table 3. Inter-material distances explained by the SIMCA models. 
Material Doxycycline Ofloxacin Ciprofloxacin Amoxycillin Azithromycin 
Doxycycline - 24 30.5 28.2 28.7 
Ofloxacin 24 - 28.1 19.3 16.3 
Ciprofloxacin 30.5 28.1 - 25.4 34.5 
Amoxicillin 28.2 19.3 25.4 - 23.5 
Azithromycin 28.7 16.3 34.5 23.5 - 
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Figure captions 
Figure 1. MSC-D1 treated NIR spectra of (a) amoxicillin/clavulanic acid; (b) azithromycin; (c) 
ciprofloxacin; (d) doxycycline; (e) ofloxacin branded antibiotic products and their main 
excipients including (f) lactose; (g) maize starch; (h) MCC and (i) talc measured using the 
PerkinElmer Spectrum Two N FT-NIR instrument equipped with NIRM. 
 
Figure 2. (a) Two-dimensional and (b) three-dimensional PCA scores plots of the MSC-D1 
spectra of branded antibiotic products of amoxicillin/clavulanic acid (blue), azithromycin (red), 
ciprofloxacin (green), doxycycline (cyan) and ofloxacin (black) measured using the 
PerkinElmer Spectrum Two N FT-NIR instrument equipped with NIRM. 
 
Figure 3. PC1 loading plot of the different brands that contributed to 51.2% of the variance 
among the data. 
 
Figure 4. PCA scores plots of the MSC-D1 spectra of antibiotics products including (a) 
amoxicillin/clavulanic acid, (b) azithromycin, (c) doxycycline and (d) ofloxacin measured using 
the PerkinElmer Spectrum Two N FT-NIR instrument equipped with NIRM. The first three PCA 
scores plots were two-dimensional whereas the latter score plot was three-dimensional. 
 
Figure 5. PCA scores plot of the MSC-D1 NIR spectra of branded (blue) and generic (red) 
ciprofloxacin batches measured using the PerkinElmer Spectrum Two N FT-NIR instrument 
equipped with NIRM. 
 
Figure 6. SIMCA models of the MSC-D1 spectra of antibiotics products including (a) 
amoxicillin/clavulanic acid, (b) azithromycin, (c) ciprofloxacin, (d) doxycycline and (e) ofloxacin 
measured using the PerkinElmer Spectrum Two N FT-NIR instrument equipped with NIRM. 
 
 
